Together, we can cross the finish line and make MDMA a medicine

The results from the first of two MAPS-sponsored Phase 3 clinical trials for MDMA-assisted therapy for PTSD were statistically significant. The full results will be published soon. Phase 3 is the final stage before seeking FDA approval for a new prescription treatment.

If successful, this treatment could transform the lives of millions of people who live with the impacts of complex trauma.

seal
NYT

In the May 4, 2021, edition of The New York Times newspaper, the world-renowned publication reveals research results from the first Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD).


Become a Psychedelic Advocate

Monthly MAPS donors sustain our work and support year-round psychedelic research, drug policy reform, public education, harm reduction, peer support, and general operations.

 





MDMA-assisted therapy is the only treatment for PTSD designated by the FDA as a breakthrough therapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist therapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored clinical trials of MDMA-assisted therapy for anxiety associated with life-threatening illness and social anxiety in autistic adults, LSD-assisted therapy for anxiety, and medical marijuana for PTSD in veterans of war. We have sponsored observational studies for ibogaine therapy for drug addiction and ayahuasca-assisted treatment for drug addiction and PTSD.

MDMA website

our education website

Our Education Programs

In addition to our clinical research programs, MAPS provides harm reduction training and services through the Zendo Project, advocates for reducing barriers to scientific research with psychedelics and marijuana, and curates educational events and webinars.

Our Values

Transparency

Information is shared openly and clearly. Communications are respectful, honest, and forthright.

Passion and Perseverance

We persist in the face of challenges. We have a sense of urgency about our work, and know that it's a long-term effort.

Intelligent Risk

Our decisions are informed by research. We try new things and learn from our mistakes.

Trust and Accountability

We value integrity and honesty, and embrace high standards.